- Home
- ASAN vs VKTX Comparison
ASAN vs VKTX Comparison
Compare ASAN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | VKTX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASAN | VKTX |
|---|---|---|
| Price | $7.26 | $30.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $16.17 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 5.3M | 2.9M |
| Earning Date | 03-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,876,000.00 | N/A |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $7.15 | $18.92 |
| 52 Week High | $20.74 | $43.15 |
Technical Indicators
Market Signals| Indicator | ASAN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 49.90 |
| Support Level | $7.30 | $29.72 |
| Resistance Level | $7.78 | $31.22 |
| Average True Range (ATR) | 0.55 | 1.92 |
| MACD | -0.02 | 0.38 |
| Stochastic Oscillator | 11.93 | 57.84 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.